BioSpace News Archive

announced that Eric A. Adams, President and Chief Executive Officer of InMed, will be presenting at the H.C. Wainwright 21st Annual Global Investment Conference in New York City

bluebird bio, Inc. (Nasdaq: BLUE) announced that updated data from the clinical development program for its investigational Lenti-D™ gene therapy in patients with cerebral adrenoleukodystrophy (CALD) will be presented at the 13th European Pediatric Neurology Society (EPNS) Congress, to be held September 17 – 21, 2019 in Athens, Greece.

Inhibrx, Inc. (Inhibrx), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced today the completion of the dose escalation portion of its Phase 1 clinical trial of INBRX-109.

BioLife Solutions, Inc. (NASDAQ: BLFS), today announced that Mustang Bio, Inc. (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, has adopted BioLife’s CryoStor cell freeze media and evo cold chain system for use in current and upcoming clinical trials.

Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company with innovative technologies for the early diagnosis of cancer, today announced that its Liver Cancer detection test has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA).

Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, today announced the appointment of David Garrett, MBA, CPA, as Chief Financial Officer.

First Clinical Trial to test the Safety and Efficacy of based on an ADC (Antibody Drug Conjugate) targeting Globo H, a glycolipid antigen found on multiple tumor types [03-September-2019] TAIPEI, Taiwan , Sept. 3, 2019 /PRNewswire/ -- OBI Pharma, a Taiwan biopharma company (TPEx: 4174), today announced that the U.S. Food and Drug Administration (FDA) has cleared an

The presence of chemicals made as the body breaks down fats, proteins, and carbohydrates can predict whether Sept. 11, 2001 first responders exposed to toxic dust at the World Trade Center site subsequently develop lung disease, a new study finds.

RCA and MAPDA Working Together to Bring Awareness about the Problem of Leftover Prescription Drugs

Fred Hutchinson Cancer Research Center and Leica Microsystems, Inc. have combined efforts to establish the Leica Microsystems Center of Excellence at Fred Hutch.